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The limitations of current pharmacological treatments of
neurodegenerative disease have led to the extensive inves-
tigation of novel compounds and nonpharmacological
approaches to modify the course of these conditions, whilst
reducing drug side effects. The definition of neuroprotection
is complex and involves both preventing cell death and
restoring function to damaged neurons, as well as restoring
neuronal numbers. The development of drugs to slow or
prevent the progression of neurodegenerative diseases might
logically evolve from an improved understanding of the etiol-
ogy and pathogenesis of these diseases. There have certainly
been major advances in these areas over the past few years
and the prospect for the introduction of “neuroprotective”
therapies is much improved over previous years.
In this context, there is growing recognition that neu-
roinflammatorymechanismsmight contribute to the cascade
of events leading to neuronal degeneration observed in
Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke,
and many other neurodegenerative diseases. Postmortem
studies and experimental models have revealed an increase in
activated glial cells and in concentrations of certain cytokines
and interleukins in brain areas such as the hippocampus,
cerebral cortex, substantia nigra, and striatum, which are
all affected in neurodegenerative diseases. Therefore, the
study of the role of neuroinflammatory mechanisms in
the pathophysiology of neurodegenerative diseases and the
potential of anti-inflammatory strategies for neuroprotection
has also attracted the interest of many authors.
Lima and colleagues explored the patterns of microglial
activation, astrocytosis, oligodendrocyte damage, myelin
impairment, and Nogo-A immunoreactivity between 3 and
30 days after experimental striatal stroke in adult rats induced
by microinjections of endothelin-1 (ET-1). They established
the temporal evolution of these neuropathological events,
which will be very relevant to future studies of neuropro-
tective drugs targeting neuroinflammation and white matter
damage.
In the study by N. Lins et al., the authors investigated
behavioral impairments and neuroinflammatory markers
following the interaction between an intranasal arbovirus
infection and the intrahippocampal injection of ME7 prion
strain in C57BL/6. They observed that virus infection exac-
erbates the microglial inflammatory response to a greater
degree in prion-infected mice, but this response was not
correlated with hippocampal-dependent behavioral deficits.
Besides its regulatory effects in the light-dark cycle, mela-
tonin is a hormone with neuroprotective, anti-inflammatory,
and antioxidant properties. J. M. Mack and colleagues
reviewed the literature about the potential role of the mela-
toninergic system in the pathogenesis and treatment of PD.
The data available so far indicates that PD is associated with
impaired brain expression of melatonin and its receptors
MT1 andMT2. Exogenous melatonin treatment presented an
outstanding neuroprotective effect in animal models of PD
induced by different toxins. Melatonin might also potentially
improve nonmotor symptoms commonly experienced by PD
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patients such as sleep and anxiety disorders, depression, and
memory dysfunction.
Another important hormone is 17𝛽-estradiol (E2), which,
in addition to its multiple actions throughout the body
and brain, exerts neuroprotective effects in both acute
and chronic neurodegenerative diseases such as cerebral
ischemia, traumatic brain injury, AD, and PD. R.Thakkar and
colleagues investigated whether 17𝛽-estradiol (E2), acting
via the estrogen receptor coregulator PELP1, can exert anti-
inflammatory effects in the ovariectomized rat and mouse
hippocampus to regulate NLRP3 inflammasome activation
after global cerebral ischemia (GCI). The authors showed
that rats subjected to GCI had significantly higher NLRP3
inflammasome activation in the hippocampus compared to
the sham animals that did not undergo ischemia. In addition,
E2 treatment suppresses both expression and activation of the
NLRP3 inflammasome at both days 1 and 3 after injury. PELP1
together with upstream inducers of NLRP3 inflammasome
activation (P2X7 and TXNIP) was essential for the anti-
inflammatory effect of E2 to regulate the NLRP3 inflamma-
some after GCI. These findings showed a new insight into
the anti-inflammatory effect of E2 in the brain, suggesting
that the NLRP3 inflammasome is a potential therapeutic
target and E2 analogues or NLRP3 inflammasome selective
inhibitors may have efficacy in the treatment of some neu-
rodegenerative disorders, such as GCI.
Calcium is a second messenger and plays an important
role in regulating a great variety of neuronal functions, such
as release of neurotransmitters, synaptic plasticity, neuronal
excitation, and gene transcription. Indeed, changes of intra-
cellular free Ca2+ concentration ([Ca2+]i) may directly alter
neuronal excitability. X. Liu and colleagues explored Ca2+
status as part of their investigation into the cardiovascular
effects of H2S, which were due to decreased oxidative stress,
via inhibition of NADPH oxidase activity in the rostral
ventrolateralmedulla (RVLM) of spontaneously hypertensive
rats (SHR). The molecular mechanisms involved in this
neuromodulator effect of H2S are not clear, although the
effects, both exogenous and endogenous, of H2S in primarily
cultured medullary neurons elevate [Ca2+]i levels, mainly
by increasing the calcium influx and mobilizing intracellular
Ca2+ stores from ER from primarily cultured rat medullary
neurons.
In HIV-associated neurocognitive disorders (HAND),
the HIV-1 transactivator protein (Tat) activated from HIV-
1-infected cells and cell membranes may lead to disruption
of tight junctions (TJs) associated with astrocytes along the
blood-brain barrier (BBB), which increase the permeability
of this barrier and can lead to HAND. Y. Chen and colleagues
investigated the relationship between occludin and amyloid-
beta (A𝛽) transfer receptors in human cerebralmicrovascular
endothelial cells (hCMEC/D3) in the context of HIV-1-
related pathology. The authors showed that HIV-1 Tat and
the Rho inhibitor hydroxyfasudil (HF) had no significant
effect on hCMEC/D3 cell viability. However, the HF signifi-
cantly inhibitedHIV-1 Tat-induced occludin dysfunction and
regulated LRP1 and RAGE expression in hCMEC/D3 cells.
Thereby, they suggested a potential protective role for HF in
HIV-1 Tat-mediated BBB destruction and A𝛽 accumulation,
revealing a new therapeutic strategy for reducing the A𝛽
burden in HAND.
Natural products have emerged as a source for potential
agents, which might ameliorate CNS neurodegeneration.
Whilst the antioxidant properties of the bee-derived plant
resin propolis have been extensively reported, its effects
on the behavioral/cognitive functions have been poorly
described. C. C. S. D. M. Da Silveira et al. examined the
neurobehavioral effects of yellow propolis, related to anxiety,
depression, and spontaneous locomotor activity in rats. The
authors also investigatedmnemonic activity as well as antiox-
idant properties of the extract, since both behavioral and cog-
nitive disorders may manifest themselves in the course of the
neurodegenerative diseases as symptoms or comorbidities.
The authors concluded that yellow propolis elicits antioxidant
activity associated with anxiolytic, antidepressant, and cog-
nitive enhancer properties. Therefore, yellow propolis shows
some promise product from natural sources in the therapy of
the central nervous system disorders, as neurodegenerative
diseases.
It is well documented that oxidative stress plays a pivotal
role in neurodegenerative diseases pathology, particularly
with AD. Another feature related to AD is the occur-
rence of dementia, in which the cholinergic neuronal enzy-
matic activity [i.e., acetylcholinesterase (AChE) and butyryl-
cholinesterase (BuChE)] is involved in the optimal impulse
transmission at cholinergic synapses. The AChE/BuChE
upregulation promotes excessive degradation of the neuro-
transmitter acetylcholine in the synaptic terminals, which
leads to cognitive dysfunctions. In fact, the treatment of
AD symptoms related to cognitive decline is based on
anticholinesterase activity modulation. D. Załuski and R.
Kuz´niewski investigated the biological activity of the 12
extracts of Eleutherococcus species related to both neurode-
generative mechanisms (i.e., oxidative stress and increased
cholinesterase activity). Their results indicated that bioactive
compounds from Eleutherococcus species are a promising
source for the protection or treatment of neurodegenerative
diseases, since the extracts were able to inhibit both AChE
and BuChE avoiding feedback loop, allied to the antioxidant
activity that in turnmay ameliorate the cognitive dysfunction
and reduce the oxidative damage, respectively.
Whilst it is clear from the studies included in this special
issue that many advances have been made in basic research
directed at improving the symptoms of neurodegenerative
diseases, there are many key issues still to be overcome.
Firstly, we remain ignorant of the genesis of the major neu-
rodegenerative diseases in individuals, although the study of
gene expression in human groups who are highly susceptible
to AD such as those with Down’s syndrome is a notable
exception. Secondly, this special issue also illustrates that the
mechanisms at play in neurodegenerative diseases are clearly
multifactorial in terms of their impact on CNS functionality,
with contributions from the immune system, antioxidant
status, changes in gene expression, and epigenetic impacts
on enzymatic function. Often, a single targeted therapeutic
intervention will successfully repair a particular issue such
as anti-inflammatory and antioxidant status, only for this
apparent advance to have little or no impact on the genesis
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and progress of the neurodegenerative condition. Thirdly,
there also remains the issue of suitability of appropriate
models employed for the assessment of possible therapeutic
initiatives.Whilst there are several animal models for various
human neurodegenerative conditions, their record in provid-
ing relevant agents which are then successful in clinical trials
has been problematic and in vitro models are very much in
their infancy.
Overall, it is imperative that we continue to progress
in our search for appropriate models, either in vivo or in
vitro, which can adequately and faithfully assess integrated
therapeutic initiatives, which can do much more than can be
done at the moment, that is, simply treating the symptoms
of these conditions and managing an inevitable decline. It is
necessary to devise treatment regimens, which not only halt
the progress of these conditions, but also one day prevent
their appearance and even restore full function in those who
have been afflicted by them. The progress reported in this
special edition suggests that, in the future, achieving these
aims might be a distant prospect but not an unattainable one.
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